The substantial reduction in price target from $50 to $13 by a major analyst like Barclays is likely to negatively impact investor sentiment and could lead to a short-term decline in Replimune Group's stock price. While the Overweight rating suggests a positive outlook on the stock, the drastic cut in the price target may overshadow this and cause concern among investors about the company's valuation or future prospects.